Protocolo de indicaciones y contraindicaciones de la derivación portosistémica percutánea intrahepática

  1. M. Aicart-Ramos
  2. J.L. Lledó
  3. B. Mateos
  4. M.A. Rodríguez-Gandía
  5. A. Albillos
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2016

Issue Title: Enfermedades del aparato digestivo (XII) Enfermedades hepáticas. Complicaciones de la cirrosis hepática

Series: 12

Issue: 12

Pages: 702-706

Type: Article

DOI: 10.1016/J.MED.2016.05.025 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

Introduction TIPS has become an important tool in the management of portal hypertension complications and has replaced surgery in its indications. Indications First used in refractory esophageal variceal bleeding, nowadays is a rescue option when conventional treatment fails in some other indications: refractory ascitis, secondary prophylaxis of esophageal or gastric variceal bleeding, refractory hepatic hydrothorax, hepatorenal syndrome and Budd Chiari syndrome. Contraindications Most of its contraindications are anatomic, due to its difficult placement. However we have to take in account, while selecting patients, the risk of cardiac and hepatic failure and encephalopathy.

Bibliographic References

  • Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic system (TIPS) in the management of portal hypertension: update 2009. American association for the study of liver diseases. Hepatology. 2010;51(1):306.
  • Rössle M. TIPS: 25 years later. J Hepatol. 2013;59(5):1081-93.
  • Copelan A, Kapoor B, Sands M. Transjugular portosystemic intrahepatic shunt: indications, contraindications and patient work-up. Semin Intervent Radiol. 2014;31:235-42.
  • Salerno F, Camma C, Enea M, Rossle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascitis: A meta-analysis of indi-vidual patient data. Gastroenterology. 2007;133:825-34.
  • Parker R. Role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Clin Liv Dis. 2014;18(2):319-34.
  • De Franchis R, Baveno VI faculty. Expanding consensus in portal hypertension: Report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepa-tol. 2015;63(3): 743-52.
  • García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early use of TIPS in patients with cirrosis and variceal bleeding. N Engl J Med. 2010;362:2370-9.
  • Norvell JP, Spivey JR. Hepatic hydrothorax. Clin Liver Dis. 2014;18:439-49.
  • Chalasani N, Clark WS, Martín LG, Kamean J, Khan MA, Patel NH, et al. Determinants of mortality in patients with advanced cirrosis after transjugular intrahepatic portosystemic system. Gastroenterol. 2000;118(1): 138-44.
  • Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2009;104:2458-66.
Data source: Dialnet